Improved activation and anti-tumor immunity via GITR engagement in CD4+ TIL are described to be mediated either by CD4+ Treg depletion via Fcγ-receptor co-engagement on innate immune cells or CD4+ Treg functionality impairment via lineage destabilization.22 The gene discussed is TNFRSF18; the disease is neoplasm.